Natixis Advisors
ASND icon

Natixis Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Natixis Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,142
Closed -$2.21M – 1600
2025
Q3 		$2.21M Buy
11,142
+492
+5% +$91.8K ﹤0.01% 1069
2025
Q2 		$1.84M Buy
+10,650
New +$1.73M ﹤0.01% 1108

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Natixis Advisors's ASND Position: Q4 2025 in Review

Natixis Advisors sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 11,142 shares — an estimated $2.21M sold.

Natixis Advisors first reported a position in ASND in Q2 2025 and held it in 2 quarters. The position peaked at $2.21M in Q3 2025. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

  • Natixis Advisors reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
  • Natixis Advisors sold 11,142 Ascendis Pharma A/S shares in Q4 2025, an estimated $2.21M.
  • Natixis Advisors first reported a position in Ascendis Pharma A/S in Q2 2025 and held it in 2 quarters.
  • Natixis Advisors's Ascendis Pharma A/S position peaked at $2.21M in Q3 2025.
  • 302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Natixis Advisors's 13F filing for Q4 2025, filed 10 Feb 2026.